# Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study

Article · Wei Y, Gong Y, Gong J, Zeng H, Zhong Z, Xiong Y, Li X

- Archive id: doi:10.1080/01443615.2026.2701996
- Published: 2026-07-24
- Venue: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
- DOI: https://doi.org/10.1080/01443615.2026.2701996
- PMID: 42495930
- Citations: 0
- Source URL: https://doi.org/10.1080/01443615.2026.2701996
- Provenance: europepmc

## Abstract

Background To compare sleeve gastrectomy, semaglutide therapy, and the Diet, Exercise, Accompany and Refresh (DEAR) weight management programme for weight control, metabolic improvement, and oncological outcomes in patients with endometrial cancer receiving fertility-sparing treatment. Methods In this prospective observational study, 53 patients received sleeve gastrectomy ( n = 10), semaglutide therapy ( n = 23), or the DEAR programme ( n = 20) after multidisciplinary assessment and shared decision-making. Anthropometric and metabolic measures and tumour response were assessed over two years. Results At 1 year, all groups lost weight; the sleeve gastrectomy group had the largest body mass index reduction compared with the semaglutide group (difference = 4.04 kg/m 2 , p \< 0.05) and the DEAR group (difference = 2.12 kg/m 2 , p \< 0.05). By 2 years, weight regain was less frequent in the DEAR group (14.3%) than in the semaglutide (55.6%) and sleeve gastrectomy (66.7%) groups ( p = 0.037). The DEAR group showed more stable metabolic improvements and the highest complete tumour remission rate (85.0%), followed by the semaglutide group (73.9%) and the sleeve gastrectomy group (60.0%). Conclusion Sleeve gastrectomy produced rapid short-term weight loss, whereas the DEAR programme showed better medium-term weight maintenance, metabolic stability, and tumour response. Integrated lifestyle support may be a useful medium-term strategy for patients seeking fertility preservation.

_Abstract reproduced under CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.